Teva, the largest generic drugmaker in the world, set the stage for the biggest pharma deal of the year by launching an unsolicited $40bn offer to buy its
nearest rival Mylan.
If consummated, the takeover would underscore the frenzied pace of mergers and acquisitions in the pharmaceutical industry. In the first three months of this year, the total value of healthcare deals reached $95.3bn, a 70 per cent rise on the same period a year ago, according to data from Thomson Reuters.
您已閱讀33%（480字），剩余67%（965字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。